問卷

TPIDB > Search Result

Search Result

篩選

List

67Cases

2022-04-01 - 2028-02-28

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-01-30 - 2028-04-01

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-03-05 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-03-15 - 2024-10-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2023-08-15 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-11-01 - 2025-05-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2026-12-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-10-13 - 2024-08-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites